Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Myelodysplastic Syndromes Clinical Trial

Official title: Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).

Clinical Trial Description

This is a Phase 1/2 study evaluating the safety and feasibility of BPX-501 T cells infused after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic stem cell transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to determine whether BPX-501 infusion can enhance immune reconstitution in those patients with hematologic disorders, with the potential for reducing the severity and duration severe acute graft versus host disease (GvHD). The trial will also evaluate the treatment of GvHD by the infusion of dimerizer drug (AP1903/rimiducid) in those subjects who present with GVHD that does not adequately respond to standard of care therapy. ;

Related Conditions & MeSH terms

• Acute Lymphoblastic Leukemia
• Anemia, Aplastic
• Cytopenia
• Hemoglobinopathies
• Hemoglobinopathy in Children
• Immunologic Deficiency Syndromes
• Leukemia
• Leukemia, Acute Myeloid (AML), Child
• Leukemia, Myeloid, Acute
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Osteopetrosis
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Primary Immune Deficiency Disorder
• Primary Immunodeficiency Diseases

• NCT number: NCT03301168
• Study type: Interventional
• Source: Bellicum Pharmaceuticals
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: April 2014
• Completion date: May 2034